Stay updated on Regeneron Press Releases
Sign up to get notified when there's something new on the Regeneron Press Releases page.

Latest updates to the Regeneron Press Releases page
- Check6 days agoChange DetectedNew items added to the press releases list include Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation (July 31, 2026) and Regeneron Reports Second Quarter 2026 Financial and Operating Results (July 30, 2026). Older entries were removed (May 15 and May 8, 2026), reflecting an updated, chronological feed on the page.SummaryDifference6%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedTwo new press releases were added (Q2 2026 financial results and Cemdisiran regulatory submissions). Two older items were removed (Dupixent EoE Phase 4 update and Q1 2026 results).SummaryDifference6%

- Check49 days agoChange DetectedNavigation now shows 'Events & Presentations' and 'Stock Information' as dedicated items, consolidating related investor resources. This changes how users access press releases, events, and stock details from the page.SummaryDifference1%

- Check56 days agoChange DetectedThe press releases list now shows fewer navigation cues because two pagination chevrons (» and ›) were removed. This may affect navigating to older releases, though it does not alter the content of the releases themselves.SummaryDifference0.6%

- Check63 days agoChange DetectedAdded a new press release item titled 'Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO' dated June 4, 2026 7:00 AM EDT. Removed the previously listed press release 'Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.' dated April 23, 2026 3:46 PM EDT.SummaryDifference2%

- Check70 days agoChange DetectedTwo new press releases were added to the press releases page: Regeneron’s Ebola antibody was recommended by the World Health Organization for investigational use in response to a Bundibugyo ebolavirus outbreak, and Otarmeni (lunsotogene parvec) received EMA filing acceptance for genetic hearing loss. At the same time, two older items were removed from the listing: the FDA approval of Otarmeni-cwha for genetic hearing loss and the Dupixent approval for young children with CSU.SummaryDifference6%

Stay in the know with updates to Regeneron Press Releases
Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.